The Competition Commission found that truck associations collectively fixed freight charges beyond government-prescribed limits and restricted market competition. The ruling directs them to cease such anti-competitive practices.
The dispute centred on whether the airport taxi operator had exclusive control over transportation services. The Commission relied on the licence agreement’s non-exclusivity clause and found no prima facie abuse of dominant position.
The Informant alleged unfair subscription cancellation and service deficiencies by an AI platform. The CCI held that the matter was essentially a dispute between the parties and did not raise competition law concerns under Section 4.
The CCI found a prima facie case against restrictive contractual clauses that allegedly prevented participants from joining competing pageants and controlled their professional activities. The matter has been referred to the Director General for investigation.
The CCI held that allegations relating to vehicle permits, GST remittance, and transport rule violations fall outside the scope of competition law. The Commission found no prima facie abuse of dominance under Section 4 of the Competition Act.
The CCI found that the investigation largely relied on comparisons with diagnostic labs and hotels rather than comparable super-specialty hospitals. The Commission ruled that such analysis was insufficient to prove exploitative pricing.
Commission found that patients undergoing elective treatment generally receive estimated treatment costs in advance and retain the ability to choose alternative hospitals. It therefore declined to treat in-patient services as a separate aftermarket under competition law.
The Competition Commission of India held that higher hospital charges alone do not establish abuse of dominance without proof that prices were excessive and unfair. The case against the hospital was closed for lack of sufficient evidence.
The CCI found that the investigation failed to compare hospital charges with similarly placed hospitals and relied on inadequate benchmarks such as standalone labs and hotels. The Commission therefore held that unfair pricing was not conclusively proved.
The CCI held that higher prices charged by a private super-specialty hospital for tests, medicines, and consumables did not automatically amount to abuse of dominance. The Commission found no sufficient evidence proving that the pricing was both excessive and unfair.
